Pharmaceutical giant Eli Lilly has made a substantial bet on the future of creative production, leading a $435.0M Series C funding round for New Limit Labs. The investment backs New Limit Labs' mission to empower elite creatives, building systems and workflows that leverage intelligent media to push the boundaries of brand world creation. The company emphasizes that AI serves as a tool, multiplying human talent and enabling the creation of brand worlds previously thought impossible.


















